-transparent.png){kind=logo}
Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study. 1993
J Verweij, and
K Krzemieniecki, and
T Kok, and
A Poveda, and
C van Pottelsberghe, and
M van Glabbeke, and
H Mouridsen
Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.
The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with oral miltefosine at a dose of 50 mg thrice daily in patients with metastatic soft tissue sarcomas. No responses were seen in 18 evaluable patients. Toxicity consisted mainly of nausea/vomiting. It is concluded that oral miltefosine has no activity in soft tissue sarcoma.
Related Publications
J Verweij, and
K Krzemieniecki, and
T Kok, and
A Poveda, and
C van Pottelsberghe, and
M van Glabbeke, and
H Mouridsen
March 2002,
European journal of cancer (Oxford, England : 1990),
J Verweij, and
K Krzemieniecki, and
T Kok, and
A Poveda, and
C van Pottelsberghe, and
M van Glabbeke, and
H Mouridsen
July 1994,
Annals of oncology : official journal of the European Society for Medical Oncology,
J Verweij, and
K Krzemieniecki, and
T Kok, and
A Poveda, and
C van Pottelsberghe, and
M van Glabbeke, and
H Mouridsen
January 1992,
European journal of cancer (Oxford, England : 1990),
J Verweij, and
K Krzemieniecki, and
T Kok, and
A Poveda, and
C van Pottelsberghe, and
M van Glabbeke, and
H Mouridsen
January 1994,
European journal of cancer (Oxford, England : 1990),
J Verweij, and
K Krzemieniecki, and
T Kok, and
A Poveda, and
C van Pottelsberghe, and
M van Glabbeke, and
H Mouridsen
March 1999,
European journal of cancer (Oxford, England : 1990),
J Verweij, and
K Krzemieniecki, and
T Kok, and
A Poveda, and
C van Pottelsberghe, and
M van Glabbeke, and
H Mouridsen
October 1987,
European journal of cancer & clinical oncology,
J Verweij, and
K Krzemieniecki, and
T Kok, and
A Poveda, and
C van Pottelsberghe, and
M van Glabbeke, and
H Mouridsen
January 1992,
European journal of cancer (Oxford, England : 1990),
J Verweij, and
K Krzemieniecki, and
T Kok, and
A Poveda, and
C van Pottelsberghe, and
M van Glabbeke, and
H Mouridsen
May 1987,
European journal of cancer & clinical oncology,
J Verweij, and
K Krzemieniecki, and
T Kok, and
A Poveda, and
C van Pottelsberghe, and
M van Glabbeke, and
H Mouridsen
August 1989,
European journal of cancer & clinical oncology,
J Verweij, and
K Krzemieniecki, and
T Kok, and
A Poveda, and
C van Pottelsberghe, and
M van Glabbeke, and
H Mouridsen
January 2000,
European journal of cancer (Oxford, England : 1990),
